Duke logo

Tolero: TP-0903 Ph 1/2 Previously Treated CLL - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out the safety of the study drug, TP-0903 at different doses and to find out if there are any effects the drug may have on patients.

What is the Condition Being Studied?

Previously treated CLL/SLL

Who Can Participate in the Study?

Adults who:
- Have an Eastern Cooperative Oncology Group (ECOG) performance status
- Have good organ function
- Have a confirmed diagnoses of CLL/small lymphocytic lymphoma (SLL) requiring therapy
- Have coagulation status

Age Group
Adults

What is Involved?

If you choose to join this study you will:
- Take the study drug, TP-0903
- Have tests, exams, and procedures
- Have blood collected
- Give a urine sample
- Have a bone marrow biopsy and aspirate
- Have a positron emission tomography (PET) scan

Study Details

Full Title
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB:PRO00100635
NCT:NCT03572634
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698